E-viri
Recenzirano
-
Jonasch, Eric; Donskov, Frede; Iliopoulos, Othon; Rathmell, W. Kimryn; Narayan, Vivek K; Maughan, Benjamin L; Oudard, Stephane; Else, Tobias; Maranchie, Jodi K; Welsh, Sarah J; Thamake, Sanjay ; Park, Eric K; Perini, Rodolfo F; Linehan, W. Marston; Srinivasan, Ramaprasad
The New England journal of medicine, 11/2021, Letnik: 385, Številka: 22Journal Article
The cause of von Hippel–Lindau disease is excess activity of the HIF-2α pathway. A total of 61 patients with renal cell carcinoma and other proliferative manifestations of the hypoxia-induced signaling pathway received belzutifan, which inhibits the HIF-2α pathway. Nearly half the patients with renal cell carcinoma had a response to treatment, and 98% had disease control.
